1-6 of 6
squamous cell carcinoma-related antigen
Close
Sort by
Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Kelda M Gardner, PA-C, Kathleen Shannon Dorcy, PhD RN, Rachele O'Leary, Donelle Rizzuto, RN, Roland B. Walter, MD PhD MS, Carole Shaw, Sunny So, RN, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Mary Beth M. Percival, MD, Anna B. Halpern, MD, Ryan D. Cassaday, MD, Janis L. Abkowitz, MD, Bethany Murphy, Niall Curley, Cody Hammer, Heather Smith, PA-C, Gabrielle A Zecha, PA-C, Frederick R. Appelbaum, MD, Soheil Meshinchi, MD PhD, Colleen Delaney, MDMSc, Todd M Cooper, DO, Katherine Tarlock, MD, Elihu H. Estey, MD, Pamela S. Becker, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2710.
https://doi.org/10.1182/blood-2018-99-116908
Published: 2018
Journal Articles

Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study

Jackie Vandermeer, BS, Allison M Winter, MD, Ajay K. Gopal, MD, Ryan D. Cassaday, MD, Brian T. Hill, MD PhD, Andrei R. Shustov, MD, Andrew J. Cowan, MD, David G. Maloney, MD PhD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Lorinda Soma, MD, Oliver W. Press, MD PhD, Stephen D. Smith, MD
Journal: Blood
Blood (2015) 126 (23): 1518.
https://doi.org/10.1182/blood.V126.23.1518.1518
Published: 2015
Journal Articles

Using Natural Language Processing to Determine Chemotherapeutic Regimens Administered within 30 Days Prior to Death in Acute Myelogenous Leukemia Patients

Hanahlyn M Park, BSN, MN(c), Vicky Sandhu, MD MPH, Paul Fearn, MBA, PhDc), Kathleen Shannon Dorcy, RN, MN, PhD, Elihu H. Estey, MD, Emily Silgard, MS
Journal: Blood
Blood (2014) 124 (21): 1267.
https://doi.org/10.1182/blood.V124.21.1267.1267
Published: 2014
Journal Articles

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Stephen J. Forman, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Leslie Popplewell, MD, Maria L Delioukina, MD, Torres Alejandra, MS, Bernadette Pulone, RN, OCN, Eileen P. Smith, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Paul O'Donnell, MD, PhD, David G. Maloney, MD, PhD, Len Farol, MD, Schickwann Tsai, MD, PhD, Laurie E. Grove, PA-C, Ajay K. Gopal, MD
Journal: Blood
Blood (2011) 118 (21): 664.
https://doi.org/10.1182/blood.V118.21.664.664
Published: 2011
Journal Articles

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Ravinder K Sandhu, Jack M. Lionberger, MD, PhD, Megan Othus, PhD, John M. Pagel, MD, PhD, Kathleen ShannonDorcy, RN, PhD, Paul C. Hendrie, MD, PhD, Stephen H. Petersdorf, MD, Pamela S Becker, MD, PhD, Frederick R. Appelbaum, M.D., Elihu H Estey, MD
Journal: Blood
Blood (2011) 118 (21): 1497.
https://doi.org/10.1182/blood.V118.21.1497.1497
Published: 2011
Journal Articles

Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms

Philipp Erben, MD, Darko Gosenca, PhD, Christoph Walz, MD, Georgia Metzgeroth, MD, Claudia Haferlach, MD, Martin C. Mùˆller, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Andreas Reiter, MD
Journal: Blood
Blood (2008) 112 (11): 3719.
https://doi.org/10.1182/blood.V112.11.3719.3719
Published: 2008